Emma Andrus

1 week ago | dermatologytimes.com | Emma Andrus |Marie Bosslett

The US FDA announced today its approval of dupilumab (Dupixent; Regeneron Pharmaceuticals, Inc. and Sanofi) for adults with bullous pemphigoid (BP), marking the first and only targeted therapy for this patient population.1The approval is supported by positive data from the pivotal phase 2/3 LIBERTY-BP ADEPT study.2 The randomized, double-blind, placebo-controlled study assessed dupilumab in a cohort of 106 adults with moderate to severe BP over the course of 52 weeks.

1 week ago | dermatologytimes.com | Emma Andrus

Journal of Cosmetic Dermatology: A Case–Control Study Examining the Differences in Vitamin D Levels Between Individuals With Rosacea and Healthy IndividualsA case–control study conducted in Iran compared vitamin D levels between 31 patients with rosacea and 31 healthy controls. Although mean vitamin D levels were higher in the rosacea group (29.9 ng/mL) than in controls (24.5 ng/mL), the difference was not statistically significant.

1 week ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life. Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.

1 week ago | dermatologytimes.com | Emma Andrus

At the 2025 Music City SCALE meeting held May 14-18 in Nashville, Tennessee, dermatologist Christina Feser, DO, FAAD, FAOCD, delivered an information-packed presentation titled “Therapeutic Updates for Hidradenitis Suppurativa.” Dermatology Times sat down with Feser to discuss key takeaways from her talk and the promising future of HS care.

1 week ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. SkinGPT by Haut.AI uses AI to visually simulate skin care results, empowering inclusive, personalized skin care and bridging clinical data with patient insight. New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes. Subgroups more likely to respond included women and those with shorter-duration, less extensive hair loss.